Jupiter Neurosciences Commits $3.33M Upfront for Exclusive US Rights to MDMA Therapeutic ALA-002
JUNS sits 60% above its 52-week low of $0.306.
Summary
Jupiter Neurosciences has entered into a term sheet to secure exclusive U.S. licensing rights for ALA-002, a next-generation MDMA therapeutic, from PharmAla Biotech. The agreement includes an upfront payment of $3.33 million, comprising $1.50 million in cash and $1.83 million in JUNS common stock, along with future milestone payments and single-digit royalties. This strategic acquisition positions Jupiter in the emerging psychedelic therapeutics market, which the company projects to be multi-billion dollars. However, this move occurs while Jupiter Neurosciences is under severe financial distress, having recently issued "going concern" warnings and facing Nasdaq delisting threats, as detailed in its May 8th 424B3 and May 14th 10-Q filings. The $1.83 million stock component of the upfront payment is highly dilutive, representing a significant percentage of the company's current market capitalization. Investors should closely watch the finalization of the definitive agreement within 90 days and the company's ability to manage the financial implications of this deal amidst its ongoing liquidity challenges.
At the time of this announcement, JUNS was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $0.31 to $3.33. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.